Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 30Prostatic Neoplasms 22Neoplasm Metastasis 20Breast Neoplasms 17Lung Neoplasms 16Colorectal Neoplasms 15Leukemia, Myeloid, Acute 14Pancreatic Neoplasms 13Ovarian Neoplasms 12Urinary Bladder Neoplasms 11Lymphoma 11Hematologic Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Myelodysplastic Syndromes 9Squamous Cell Carcinoma of Head and Neck 8Sarcoma, Kaposi 8Pheochromocytoma 8Multiple Myeloma 8Melanoma 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Endometrial Neoplasms 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Neuroendocrine Tumors 7Mouth Neoplasms 7Kidney Neoplasms 7Glioma 7Thyroid Neoplasms 6

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × NIH × Carcinoma, Endometrioid × Clear all
NCT05112601 2026-04-21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
81 enrolled
Gynecologic

Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡